Sign in
CompletedPhase 4

Comparative Effectiveness of Triple Versus Quadruple Therapy in the Treatment of Helicobacter Pylori Induced Gastritis

Key facts

Who runs it
Azfar Farogh
Where
Pakistan1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
752 people enrolled
Started
5 Jan 2024
Ended
30 Dec 2024
Type of study
Interventional, 2 groups
Treatments tested
  • Triple Therapy
  • Quadruple Therapy
Record updated
31 December 2025

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Adults aged 18-65 years; Confirmed Helicobacter pylori infection based on a positive stool antigen test; Willing and able to provide written informed consent

Who cannot take part

  • Prior H. pylori eradication therapy
  • History of gastrointestinal bleeding, peptic ulcer perforation, or prior gastric surgery
  • Current use of proton pump inhibitors or antibiotics within the previous six weeks
  • Use of traditional (Hakeem) medications or herbal remedies affecting gastric function
  • History of allergy or hypersensitivity to any of the study drugs (omeprazole, amoxicillin, clarithromycin, metronidazole, tetracycline, or bismuth compounds)
  • Chronic renal failure or hepatic dysfunction
  • Psychiatric illness or inability to comply with treatment and follow-up
  • Pregnancy or lactation
  • -

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This randomized controlled trial is designed to compare the efficacy of standard triple therapy versus bismuth-based quadruple therapy for the eradication of Helicobacter pylori-induced gastritis. The study is being conducted at Shahida Islam Medical College, Lodhran, Pakistan. Adult patients with confirmed H. pylori infection are randomly allocated to receive either a 14-day triple therapy regimen or a 14-day bismuth-based quadruple therapy regimen. Eradication of H. pylori is assessed six weeks after completion of treatment using stool antigen testing. The primary outcome measure is the proportion of patients achieving successful eradication of H. pylori.

The 2 groups in the trial

  • Triple Therapy GroupTreatment being tested

    Participants received Omeprazole 40 mg twice daily, Amoxicillin 1 g twice daily, and Clarithromycin 500 mg twice daily for 14 days.

    Treatment: Triple Therapy

  • Quadruple Therapy GroupTreatment being tested

    Participants received Omeprazole 40 mg twice daily, Metronidazole 400 mg three times daily, Tetracycline 500 mg every six hours, and Bismuth subsalicylate for 14 days.

    Treatment: Quadruple Therapy

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Comparative Effectiveness of Triple Versus Quadruple Therapy in the Treatment of Helicobacter Pylori Induced Gastritis: A Randomized Controlled Trial
Record updated
31 December 2025